펩티드 치료제 시장 : 세계 업계 분석, 규모, 점유율, 성장, 동향, 예측(2022-2031년)

TMR's report on the global peptide therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global peptide therapeutics market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global peptide therapeutics market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the peptide therapeutics market.

The report delves into the competitive landscape of the global peptide therapeutics market. Key players operating in the global peptide therapeutics market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global peptide therapeutics market profiled in this report.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Peptide Therapeutics Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Definition
  • 4.1.2. Industry Evolution / Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Peptide Therapeutics Market Analysis and Forecast, 2017-2031

5. Key Insights

• 5.1. White Space Analysis
• 5.2. Porter's Analysis
• 5.3. Pipeline Analysis (Phase III)
• 5.4. Peptide Drug Chemical Structure Trend Analysis
• 5.5. Separation Media for Peptide Drug Manufacturing
• 5.6. Covid-19 Impact Analysis

6. Global Peptide Therapeutics Market Analysis and Forecast, by Application

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast, by Application, 2017-2031
  • 6.3.1. Cancer
  • 6.3.2. Metabolic
  • 6.3.3. CVD
  • 6.3.4. Respiratory
  • 6.3.5. GIT
  • 6.3.6. Anti-infective
  • 6.3.7. Dermatology
  • 6.3.8. CNS
  • 6.3.9. Renal
• 6.4. Market Attractiveness Analysis, by Application

7. Global Peptide Therapeutics Market Analysis and Forecast, by Route of Administration

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast, by Route of Administration, 2017-2031
  • 7.3.1. Parenteral
  • 7.3.2. Oral
• 7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Peptide Therapeutics Market Analysis and Forecast, by Type

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast, by Type, 2017-2031
  • 8.3.1. Innovative
  • 8.3.2. Generic
• 8.4. Market Attractiveness Analysis, by Type

9. Global Peptide Therapeutics Market Analysis and Forecast, by Technology

• 9.1. Introduction & Definition
• 9.2. Key Findings / Developments
• 9.3. Market Value Forecast, by Technology, 2017-2031
  • 9.3.1. Liquid Phase
  • 9.3.2. Solid Phase
  • 9.3.3. Hybrid Phase
• 9.4. Market Attractiveness Analysis, by Technology

10. Global Peptide Therapeutics Market Analysis and Forecast, by Type of Molecule

• 10.1. Introduction & Definition
• 10.2. Key Findings / Developments
• 10.3. Market Value Forecast, by Type of Molecule, 2017-2031
  • 10.3.1. Vasopressin
  • 10.3.2. Somatostatin
  • 10.3.3. Calcitonin
  • 10.3.4. Natriuretic
• 10.4. Market Attractiveness Analysis, by Type of Molecule

11. Global Peptide Therapeutics Market Analysis and Forecast, by API Peptide Type

• 11.1. Introduction & Definition
• 11.2. Key Findings / Developments
• 11.3. Market Value Forecast, by API Peptide Type ,2017-2031
  • 11.3.1. In-house
  • 11.3.2. CMO
• 11.4. Market Attractiveness Analysis, by API Peptide Type

12. Global Peptide Therapeutics Market Analysis and Forecast, by Region

• 12.1. Key Findings
• 12.2. Market Value Forecast, by Region
  • 12.2.1. North America
  • 12.2.2. Europe
  • 12.2.3. Asia Pacific
  • 12.2.4. Latin America
  • 12.2.5. Middle East & Africa
• 12.3. Market Attractiveness Analysis, by Region

13. North America Peptide Therapeutics Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Application,2017-2031
  • 13.2.1. Cancer
  • 13.2.2. Metabolic
  • 13.2.3. CVD
  • 13.2.4. Respiratory
  • 13.2.5. GIT
  • 13.2.6. Anti-infective
  • 13.2.7. Dermatology
  • 13.2.8. CNS
  • 13.2.9. Renal
• 13.3. Market Value Forecast, by End-user,2017-2031
  • 13.3.1. Parenteral
  • 13.3.2. Oral
• 13.4. Market Value Forecast, by Type, 2017-2031
  • 13.4.1. Innovative
  • 13.4.2. Generic
• 13.5. Market Value Forecast, by Technology, 2017-2031
  • 13.5.1. Liquid Phase
  • 13.5.2. Solid Phase
  • 13.5.3. Hybrid Phase
• 13.6. Market Value Forecast, by Type of Molecule, 2017-2031
  • 13.6.1. Vasopressin
  • 13.6.2. Somatostatin
  • 13.6.3. Calcitonin
  • 13.6.4. Natriuretic
• 13.7. Market Value Forecast, by API Peptide Type, 2017-2031
  • 13.7.1. In-house
  • 13.7.2. CMO
• 13.8. Market Value Forecast, by Country, 2017-2031
  • 13.8.1. U.S.
  • 13.8.2. Canada
• 13.9. Market Attractiveness Analysis
  • 13.9.1. By Application
  • 13.9.2. By Route of Administration
  • 13.9.3. By Type
  • 13.9.4. By Technology
  • 13.9.5. By Type of Molecule
  • 13.9.6. By API Peptide Type
  • 13.9.7. By Country

14. Europe Peptide Therapeutics Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast, by Application, 2017-2031
  • 14.2.1. Cancer
  • 14.2.2. Metabolic
  • 14.2.3. CVD
  • 14.2.4. Respiratory
  • 14.2.5. GIT
  • 14.2.6. Anti-infective
  • 14.2.7. Dermatology
  • 14.2.8. CNS
  • 14.2.9. Renal
• 14.3. Market Value Forecast, by End-user, 2017-2031
  • 14.3.1. Parenteral
  • 14.3.2. Oral
• 14.4. Market Value Forecast, by Type, 2017-2031
  • 14.4.1. Innovative
  • 14.4.2. Generic
• 14.5. Market Value Forecast, by Technology, 2017-2031
  • 14.5.1. Liquid Phase
  • 14.5.2. Solid Phase
  • 14.5.3. Hybrid Phase
• 14.6. Market Value Forecast, by Type of Molecule, 2017-2031
  • 14.6.1. Vasopressin
  • 14.6.2. Somatostatin
  • 14.6.3. Calcitonin
  • 14.6.4. Natriuretic
• 14.7. Market Value Forecast, by API Peptide Type, 2017-2031
  • 14.7.1. In-house
  • 14.7.2. CMO
• 14.8. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 14.8.1. Germany
  • 14.8.2. U.K.
  • 14.8.3. France
  • 14.8.4. Spain
  • 14.8.5. Italy
  • 14.8.6. Rest of Europe
• 14.9. Market Attractiveness Analysis
  • 14.9.1. By Application
  • 14.9.2. By Route of Administration
  • 14.9.3. By Type
  • 14.9.4. By Technology
  • 14.9.5. By Type of Molecule
  • 14.9.6. By API Peptide Type
  • 14.9.7. By Country/Sub-region

15. Asia Pacific Peptide Therapeutics Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast, by Application, 2017-2031
  • 15.2.1. Cancer
  • 15.2.2. Metabolic
  • 15.2.3. CVD
  • 15.2.4. Respiratory
  • 15.2.5. GIT
  • 15.2.6. Anti-infective
  • 15.2.7. Dermatology
  • 15.2.8. CNS
  • 15.2.9. Renal
• 15.3. Market Value Forecast, by End-user, 2017-2031
  • 15.3.1. Parenteral
  • 15.3.2. Oral
• 15.4. Market Value Forecast, by Type, 2017-2031
  • 15.4.1. Innovative
  • 15.4.2. Generic
• 15.5. Market Value Forecast, by Technology, 2017-2031
  • 15.5.1. Liquid Phase
  • 15.5.2. Solid Phase
  • 15.5.3. Hybrid Phase
• 15.6. Market Value Forecast, by Type of Molecule, 2017-2031
  • 15.6.1. Vasopressin
  • 15.6.2. Somatostatin
  • 15.6.3. Calcitonin
  • 15.6.4. Natriuretic
• 15.7. Market Value Forecast, by API Peptide Type, 2017-2031
  • 15.7.1. In-house
  • 15.7.2. CMO
• 15.8. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 15.8.1. China
  • 15.8.2. Japan
  • 15.8.3. India
  • 15.8.4. Australia & New Zealand
  • 15.8.5. Rest of Asia Pacific
• 15.9. Market Attractiveness Analysis
  • 15.9.1. By Application
  • 15.9.2. By Route of Administration
  • 15.9.3. By Type
  • 15.9.4. By Technology
  • 15.9.5. By Type of Molecule
  • 15.9.6. By API Peptide Type
  • 15.9.7. By Country/Sub-region

16. Latin America Peptide Therapeutics Market Analysis and Forecast

• 16.1. Introduction
  • 16.1.1. Key Findings
• 16.2. Market Value Forecast, by Application, 2017-2031
  • 16.2.1. Cancer
  • 16.2.2. Metabolic
  • 16.2.3. CVD
  • 16.2.4. Respiratory
  • 16.2.5. GIT
  • 16.2.6. Anti-infective
  • 16.2.7. Dermatology
  • 16.2.8. CNS
  • 16.2.9. Renal
• 16.3. Market Value Forecast, by End-user, 2017-2031
  • 16.3.1. Parenteral
  • 16.3.2. Oral
• 16.4. Market Value Forecast, by Type, 2017-2031
  • 16.4.1. Innovative
  • 16.4.2. Generic
• 16.5. Market Value Forecast, by Technology,2017-2031
  • 16.5.1. Liquid Phase
  • 16.5.2. Solid Phase
  • 16.5.3. Hybrid Phase
• 16.6. Market Value Forecast, by Type of Molecule, 2017-2031
  • 16.6.1. Vasopressin
  • 16.6.2. Somatostatin
  • 16.6.3. Calcitonin
  • 16.6.4. Natriuretic
• 16.7. Market Value Forecast, by API Peptide Type, 2017-2031
  • 16.7.1. In-house
  • 16.7.2. CMO
• 16.8. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 16.8.1. Brazil
  • 16.8.2. Mexico
  • 16.8.3. Rest of Latin America
• 16.9. Market Attractiveness Analysis
  • 16.9.1. By Application
  • 16.9.2. By Route of Administration
  • 16.9.3. By Type
  • 16.9.4. By Technology
  • 16.9.5. By Type of Molecule
  • 16.9.6. By API Peptide Type
  • 16.9.7. By Country/Sub-region

17. Middle East & Africa Peptide Therapeutics Market Analysis and Forecast

• 17.1. Introduction
  • 17.1.1. Key Findings
• 17.2. Market Value Forecast, by Application, 2017-2031
  • 17.2.1. Cancer
  • 17.2.2. Metabolic
  • 17.2.3. CVD
  • 17.2.4. Respiratory
  • 17.2.5. GIT
  • 17.2.6. Anti-infective
  • 17.2.7. Dermatology
  • 17.2.8. CNS
  • 17.2.9. Renal
• 17.3. Market Value Forecast, by End-user, 2017-2031
  • 17.3.1. Parenteral
  • 17.3.2. Oral
• 17.4. Market Value Forecast, by Type, 2017-2031
  • 17.4.1. Innovative
  • 17.4.2. Generic
• 17.5. Market Value Forecast, by Technology, 2017-2031
  • 17.5.1. Liquid Phase
  • 17.5.2. Solid Phase
  • 17.5.3. Hybrid Phase
• 17.6. Market Value Forecast, by Type of Molecule, 2017-2031
  • 17.6.1. Vasopressin
  • 17.6.2. Somatostatin
  • 17.6.3. Calcitonin
  • 17.6.4. Natriuretic
• 17.7. Market Value Forecast, by API Peptide Type, 2017-2031
  • 17.7.1. In-house
  • 17.7.2. CMO
• 17.8. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 17.8.1. GCC Countries
  • 17.8.2. South Africa
  • 17.8.3. Rest of Middle East & Africa
• 17.9. Market Attractiveness Analysis
  • 17.9.1. By Application
  • 17.9.2. By Route of Administration
  • 17.9.3. By Type
  • 17.9.4. By Technology
  • 17.9.5. By Type of Molecule
  • 17.9.6. By API Peptide Type
  • 17.9.7. By Country/Sub-region

18. Competition Landscape

• 18.1. Market Player - Competition Matrix (by tier and size of companies)
• 18.2. Market Share Analysis, by Company, 2021
• 18.3. Company Profiles
  • 18.3.1. Amgen, Inc.
    • 18.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 18.3.1.2. Product Portfolio
    • 18.3.1.3. SWOT Analysis
    • 18.3.1.4. Strategic Overview
  • 18.3.2. Bachem Holding AG
    • 18.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 18.3.2.2. Product Portfolio
    • 18.3.2.3. SWOT Analysis
    • 18.3.2.4. Strategic Overview
  • 18.3.3. Eli Lilly and Company
    • 18.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 18.3.3.2. Product Portfolio
    • 18.3.3.3. SWOT Analysis
    • 18.3.3.4. Strategic Overview
  • 18.3.4. F. Hoffmann-La Roche Ltd.
    • 18.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 18.3.4.2. Product Portfolio
    • 18.3.4.3. SWOT Analysis
    • 18.3.4.4. Strategic Overview
  • 18.3.5. GlaxoSmithKline plc
    • 18.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 18.3.5.2. Product Portfolio
    • 18.3.5.3. SWOT Analysis
    • 18.3.5.4. Strategic Overview
  • 18.3.6. Novartis AG
    • 18.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 18.3.6.2. Product Portfolio
    • 18.3.6.3. SWOT Analysis
    • 18.3.6.4. Strategic Overview
  • 18.3.7. Pfizer, Inc.
    • 18.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 18.3.7.2. Product Portfolio
    • 18.3.7.3. SWOT Analysis
    • 18.3.7.4. Strategic Overview
  • 18.3.8. Sanofi
    • 18.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 18.3.8.2. Product Portfolio
    • 18.3.8.3. SWOT Analysis
    • 18.3.8.4. Strategic Overview
  • 18.3.9. Takeda Pharmaceutical Company Limited
    • 18.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 18.3.9.2. Product Portfolio
    • 18.3.9.3. SWOT Analysis
    • 18.3.9.4. Strategic Overview
  • 18.3.10. Teva Pharmaceutical Industries Ltd.
    • 18.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 18.3.10.2. Product Portfolio
    • 18.3.10.3. SWOT Analysis
    • 18.3.10.4. Strategic Overview